RT info:eu-repo/semantics/article
T1 C1q and HBHA-specific IL-13 levels as surrogate plasma biomarkers for monitoring tuberculosis treatment efficacy: a cross-sectional cohort study in Paraguay
A1 Russomando Alvarez, Graciela Mabel
A1 Sanabria Martínez, Diana Leticia
A1 Díaz Acosta, Chyntia Carolina
A1 Arenas, Rossana
A1 Rojas Vera, Leticia Elizabeth
A1 Franco, Laura Ximena
A1 Arenas Chaparro, María Rossana
A1 Delogu, Giovanni
A1 Bousso Ndiaye, Mame Diarra
A1 Bayaa, Rim
A1 Rakotosamimanana, Niaina
A1 Goletti, Delia
A1 Hoffmann, Jonathan
A2 Universidad Nacional de Asunción. Instituto de Investigaciones en Ciencias de la Salud
AB Introduction: New diagnostic tools are needed to rapidly assess the efficacy of pulmonary tuberculosis (PTB) treatment. The aim of this study was to evaluate several immune biomarkers in an observational and cross-sectional cohort study conducted in Paraguay.Methods: Thirty-two patients with clinically and microbiologically confirmed PTB were evaluated before starting treatment (T0), after 2 months of treatment (T1) and at the end of treatment (T2). At each timepoint plasma levels of IFN-y, 17 pro- and anti-inflammatory cytokines/chemokines and complement factors C1q, C3 and C4 were assessed in unstimulated and Mtb-specific stimulated whole blood samples using QuantiFERON-TB gold plus and recombinant Mycobacterium smegmatis heparin binding hemagglutinin (rmsHBHA) as stimulation antigen. Complete blood counts and liver enzyme assays were also evaluated and correlated with biomarker levels in plasma.Results: In unstimulated plasma, C1q (P<0.001), C4 (P<0.001), hemoglobin (P<0.001), lymphocyte proportion (P<0.001) and absolute white blood cell count (P=0.01) were significantly higher in PTB patients at baseline than in cured patients. C1q and C4 levels were found to be related to Mycobacterium tuberculosis load in sputum. Finally, a combinatorial analysis identified a plasma host signature comprising the detection of C1q and IL-13 levels in response to rmsHBHA as a tool differentiating PTB patients from cured TB profiles, with an AUC of 0.92 (sensitivity 94% and specificity 79%).Conclusion: This observational study provides new insights on host immune responses throughout anti-TB treatment and emphasizes the role of host C1q and HBHA-specific IL-13 response as surrogate plasma biomarkers for monitoring TB treatment efficacy.
PB Frontiers Media S.A.
YR 2024
FD 2024-03-13
LK http://hdl.handle.net/20.500.14066/4587
UL http://hdl.handle.net/20.500.14066/4587
LA eng
NO Russomando, G., Sanabria, D., Díaz Acosta, C. C., Rojas, L., Franco L., Arenas, R., Delogu, G., Bousso Ndiaye M. D., Bayaa, R., Rakotosamimanana, N., Goletti, D., & Hoffmann, J. (2024). C1q and HBHA-specific IL-13 levels as surrogate plasma biomarkers for monitoring tuberculosis treatment efficacy: a cross-sectional cohort study in Paraguay. Frontiers in Immunology, 15, Article 1308015.https://doi.org/10.3389/fimmu.2024.1308015
NO Correspondence: Graciela Russomando, grusso@rieder.net.py; Jonathan Hoffmann, jonathan.hoffmann@fondation-merieux.org
NO Consejo Nacional de Ciencia y Tecnología
DS MINDS@UW
RD 04-sep-2026